Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Boston Scientific CRT lead

This article was originally published in The Gray Sheet

Executive Summary

Boston Scientific announces May 16 FDA market go-ahead for its Acuity Spiral left ventricular lead for cardiac resynchronization devices, such as its Cognis cardiac resynchronization therapy defibrillator (CRT-D) approved May 13 (1"The Gray Sheet" May 19, 2008, In Brief). Acuity Spiral has a spiral fixation design and small lead tip, tapering from size 4.1 French to 2.6 French. The company is sponsoring a five-year, 1,700-patient, 125-center registry to study the real-world performance of Acuity Spiral with the Latitude remote monitoring system. Acuity Spiral earned a CE mark in March (2"The Gray Sheet" March 10, 2008, p. 12)

Latest Headlines
See All
UsernamePublicRestriction

Register

MT026140

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel